#+TITLE: Sphingolipid Degradation: Fabry
#+AUTHOR: Matthew Henderson, PhD, FCACB
#+DATE: \today

:PROPERTIES:
#+DRAWERS: PROPERTIES
#+LaTeX_CLASS: beamer
#+LaTeX_CLASS_OPTIONS: [presentation, smaller]
#+BEAMER_THEME: Ilmenau
#+BEAMER_COLOR_THEME: whale
#+BEAMER_FRAME_LEVEL: 2
#+COLUMNS: %40ITEM %10BEAMER_env(Env) %9BEAMER_envargs(Env Args) %4BEAMER_col(Col) %10BEAMER_extra(Extra)
#+OPTIONS: H:2 toc:nil
#+PROPERTY: header-args:R :session *R*
#+PROPERTY: header-args :cache no
#+PROPERTY: header-args :tangle yes
#+STARTUP: beamer
#+STARTUP: overview
#+STARTUP: hidestars
#+STARTUP: indent
# #+BEAMER_HEADER: \subtitle{Part 1: Maple Syrup Urine Diseas}
#+BEAMER_HEADER: \institute[NSO]{Newborn Screening Ontario | The University of Ottawa}
#+BEAMER_HEADER: \titlegraphic{\includegraphics[height=1cm,keepaspectratio]{../logos/NSO_logo.pdf}\includegraphics[height=1cm,keepaspectratio]{../logos/cheo-logo.png} \includegraphics[height=1cm,keepaspectratio]{../logos/UOlogoBW.eps}}
#+latex_header: \hypersetup{colorlinks,linkcolor=white,urlcolor=blue}
#+LaTeX_header: \usepackage{textpos}
#+LaTeX_header: \usepackage{textgreek}
#+LaTeX_header: \usepackage[version=4]{mhchem}
#+LaTeX_header: \usepackage{chemfig}
#+LaTeX_header: \usepackage{siunitx}
#+LaTeX_header: \usepackage{gensymb}
#+LaTex_HEADER: \usepackage[usenames,dvipsnames]{xcolor}
#+LaTeX_HEADER: \usepackage[T1]{fontenc}
#+LaTeX_HEADER: \usepackage{lmodern}
#+LaTeX_HEADER: \usepackage{verbatim}
#+LaTeX_HEADER: \usepackage{tikz}
#+LaTeX_HEADER: \usetikzlibrary{shapes.geometric,arrows,decorations.pathmorphing,backgrounds,positioning,fit,petri}
:END:
#+BEGIN_LaTeX
%\logo{\includegraphics[width=1cm,height=1cm,keepaspectratio]{../logos/NSO_logo_small.pdf}~%
%    \includegraphics[width=1cm,height=1cm,keepaspectratio]{../logos/UOlogoBW.eps}%
%}

\vspace{220pt}
\beamertemplatenavigationsymbolsempty
\setbeamertemplate{caption}[numbered]
\setbeamerfont{caption}{size=\tiny}
% \addtobeamertemplate{frametitle}{}{%
% \begin{textblock*}{100mm}(.85\textwidth,-1cm)
% \includegraphics[height=1cm,width=2cm]{cat}
% \end{textblock*}}

\tikzstyle{chemical} = [rectangle, rounded corners, text width=5em, minimum height=1em,text centered, draw=black, fill=none]
\tikzstyle{hardware} = [rectangle, rounded corners, text width=5em, minimum height=1em,text centered, draw=black, fill=gray!30]
\tikzstyle{ms} = [rectangle, rounded corners, text width=5em, minimum height=1em,text centered, draw=orange, fill=none]
\tikzstyle{msw} = [rectangle, rounded corners, text width=7em, minimum height=1em,text centered, draw=orange, fill=none]
\tikzstyle{label} = [rectangle,text width=8em, minimum height=1em, text centered, draw=none, fill=none]
\tikzstyle{hl} = [rectangle, rounded corners, text width=5em, minimum height=1em,text centered, draw=black, fill=red!30]
\tikzstyle{box} = [rectangle, rounded corners, text width=5em, minimum height=5em,text centered, draw=black, fill=none]
\tikzstyle{arrow} = [thick,->,>=stealth]
\tikzstyle{hl-arrow} = [ultra thick,->,>=stealth,draw=red]

#+END_LaTeX

* Introduction

** Fabry

- AKA: angiokeratoma corporis diffusum universale
- Second most common LSD
- 1:339,000 heterozygote females in the UK
- First described in 1898 independently by Anderson and Fabry
  - Dermatologists
- Defect in \alpha-galactosidase A (ceramide trihexosidase)
  - Inability to cleave terminal galactose from the sphingolipid globotriasylceramide Gb3 (galactosylgalactosylglucoceramide)
  - 3 to 20% activity in hemizygote males
- Lack of \alpha-GalA leads to accumulation of Gb3 in blood vessels and other tissues
  - wide range of symptoms including kidney, heart, and skin symptoms
  - \uparrow [Gb3] in kidney and blood group B antigenic glycosphingolipid

** Sphingolipid degradation

#+CAPTION[deg]:Sphingolipid degradation
#+NAME: fig:sld
#+ATTR_LaTeX: :width 0.6\textwidth
[[file:./figures/sl_degradation.png]]


**  Globotriasylceramide (Gb3): the Fabry lipid
#+CAPTION[gluc]:globotriasylceramide
#+NAME: fig:galac 
#+ATTR_LaTeX: :width 0.5\textwidth
[[file:./figures/globotriasylceramide.png]]

** \alpha-galactosidase A
#+CAPTION[block]:\beta-glucocerebrosidase
#+NAME: fig:sidase
#+ATTR_LaTeX: :width 0.5\textwidth
[[file:./figures/galactosidaseA.png]]

- Located in the lumen of lysosomes

** Lysosomal Trafficking

#+CAPTION[traf]:Lysosomal Trafficking
#+NAME: fig:traf
#+ATTR_LaTeX: :width 0.8\textwidth
[[file:./figures/lysosome_trafficking.jpeg]]
- Sortilin dependant pathway
  - Not affected in ML II & III

** Sortilin

- Sortilin is a type I transmembrane protein found in lysosomes
  - can transport several lysosomal proteins from the TGN or PM to the endosomes,
     - Several of these proteins exhibit normal levels in some cell types and tissues of I-cell disease patients
- Tissues from sortilin knock-out mice exhibit normal morphology
- Sortilin may transport selected acid hydrolases in a subset of cell types
- under stress conditions (e.g. Man-6-P pathway is deficient) 

** Megalin 
- a cell surface receptor involved in reabsorption of proteins at the kidney proximal tubule
- megalin mediated endocytosis of \alpha-galactosidase kidney proximal tubule 
- megalin also mediates the endocytosis of \alpha-galactosidase in renal podocytes

** Genetics
- The \alpha-galactosidase A gene is on the X chromosome
  - Xq22.1
- X-linked with penetrance in female heterozygotes
  - may be considered X-linked dominant
- More that 300 of mutations have been found
- Single nucleotide missense mutations identified in the majority of families
  - Most private mutations

* Clinical Findings

** Signs and Symptoms

- postprandial pain or diarrhea
  - may be sole complaint
- degradation of interphalangeal joints
- cerebrovascular - stroke, seizures
- ocular lesions


| Age         | Signs                                           |
|-------------+-------------------------------------------------|
| Childhood   | Pain in extremities, fever, Fabry crisis [fn:1] |
| Adolescence | Angiokeratomas                                  |
| Adulthood   | Central nervous system symptoms                 |
|             | Myocardial and pulmonary disease                |
| Middle age  | Renal failure, lymphedema                       |


[fn:1] May be induced by heat, cold, fatigue or emotional stress


* Laboratory Investigations

** Biochemistry
- Deficient \alpha-galactosidase A activity in leukocytes
- NBS via \alpha-galactosidase A activity in DBS
  - Taiwan, MO, IL
- Elevated urine Gb3 and Gb2 in hemizygote males and heterozygote females
- Plasma lyso-Gb3 is a sensitive biomarker

** Pathology

***                                                                 :BMCOL:
:PROPERTIES:
:BEAMER_col: 0.5
:END:
- Widespread deposition of Gb3
- Vacuoles seen in variety of cells, \uparrow endothelium of blood vessels

***                                                                 :BMCOL:
:PROPERTIES:
:BEAMER_col: 0.5
:END:

#+CAPTION[em]:EM showing concentric or lamellar structure of lysosomal inclusions in Fabry disease renal biopsy
#+NAME: fig:biopsy
#+ATTR_LaTeX: :width 0.7\textwidth
[[file:./figures/Fabrys-disease.jpg]]




* Treatment

** Treatment
- Alleviate pain
- Treat renal and cardiac disease
  - Dialysis or renal transplantation
- Long term experience with ERT
  - agalsidase alpha or beta)
  - Reduces left ventricular hypertrophy
  - Less effect on renal function
  - Does not prevent progression
- Chaperone therapy - migalastat
  - Amenable mutations

** Next time

- Disorders of Sphingolipid Degradation continued...

